Molecular structure of Zotepine, CAS Number: 26615-21-4
Zotepine (CAS 26615-21-4)
See product citations (3)
Application:
Zotepine is an SR-2A and D2DR inhibitor and Histamine H1 receptor antagonist
CAS Number:
26615-21-4
Molecular Weight:
331.86
Molecular Formula:
C18H18ClNOS
Supplemental Information:
This is classified as a Dangerous Good for transport and may be subject to additional shipping charges.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Zotepine functions as a dopamine D2 and serotonin 5-HT2 receptor antagonist. It acts by blocking the binding of dopamine and serotonin to their respective receptors, thereby inhibiting their signaling pathways. This interference with neurotransmitter binding results in a decrease in the activity of dopamine and serotonin in the brain. Zotepine′s function in experimental applications involves its ability to modulate neurotransmitter activity, providing insights into the role of dopamine and serotonin in various biological processes.
Zotepine (CAS 26615-21-4) References
- Zotepine for schizophrenia. | Fenton, M., et al. 2000. Cochrane Database Syst Rev. CD001948. PMID: 10796671
- Effects of zotepine and olanzapine on noradrenaline transporter in cultured bovine adrenal medullary cells. | Yoshimura, R., et al. 2005. Hum Psychopharmacol. 20: 477-84. PMID: 16158449
- [The biochemical effect profile of zotepine in comparison with other neuroleptics]. | Ackenheil, M. 1991. Fortschr Neurol Psychiatr. 59 Suppl 1: 2-9. PMID: 1683335
- Zotepine for schizophrenia. | DeSilva, P., et al. 2006. Cochrane Database Syst Rev. 2006: CD001948. PMID: 17054149
- Zotepine-induced spontaneous ejaculation. | Wang, PW., et al. 2008. Int J Clin Pharmacol Ther. 46: 571-3. PMID: 19000555
- Zotepine: a clinical review. | Green, B. 2009. Expert Opin Drug Metab Toxicol. 5: 181-6. PMID: 19199377
- Zotepine versus other atypical antipsychotics for schizophrenia. | Komossa, K., et al. 2010. Cochrane Database Syst Rev. CD006628. PMID: 20091601
- Safety evaluation of zotepine for the treatment of schizophrenia. | Riedel, M., et al. 2010. Expert Opin Drug Saf. 9: 659-66. PMID: 20486863
- The efficacy of zotepine in schizophrenia: A meta-analysis of BPRS and improvement scale scores. | Butler Andrew Wighton Claire P Welch Jack A Tweed Bill D Byrom Chris Reynolds, A. 2000. Int J Psychiatry Clin Pract. 4: 19-27. PMID: 24927305
- Intranasal Zotepine Nanosuspension: intended for improved brain distribution in rats. | Pailla, SR., et al. 2019. Daru. 27: 541-556. PMID: 31256410
- Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. | Huhn, M., et al. 2019. Lancet. 394: 939-951. PMID: 31303314
- Brain-Targeted Intranasal Delivery of Zotepine Microemulsion: Pharmacokinetics and Pharmacodynamics. | Pailla, SR., et al. 2022. Pharmaceutics. 14: PMID: 35631564
- The central anti-serotonin activity of zotepine, a new neuroleptic, in rats. | Shimomura, K., et al. 1982. Jpn J Pharmacol. 32: 405-12. PMID: 6125612
- [Pharmacokinetics of zotepine and various factors affecting that of zotepine]. | Tanaka, O. 1996. Nihon Shinkei Seishin Yakurigaku Zasshi. 16: 49-52. PMID: 8905790
Inhibitor of:
D2DR, Histamine H1 Receptor, Serotonin, and SR-2A.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Zotepine, 10 mg | sc-360895 | 10 mg | $67.00 | |||
Zotepine, 50 mg | sc-360895A | 50 mg | $251.00 |